A novel recombinant tumor necrosis factor-alpha mutant with increased anti-tumor activity and lower toxicity. |
| |
Authors: | S Nakamura A Kato T Masegi M Fukuoka K Kitai H Ogawa Y Ichikawa M Maeda N Watanabe Y Kohgo |
| |
Institution: | Biotechnology Research Laboratories, Teijin Limited, Tokyo, Japan. |
| |
Abstract: | We prepared a novel recombinant tumor necrosis factor-alpha (TNF) mutant (mutant 471), in which 7 N-terminal amino-acids were deleted and Pro8Ser9Asp10 was replaced by ArgLysArg, and compared its biological activity with that of wild-type recombinant TNF. Mutant 471 had a 7-fold higher anti-tumor activity against murine L-M cells in vitro, and a higher binding activity to TNF receptors on L-M cells, than wild-type TNF. Furthermore, mutant 471 showed a higher anti-tumor effect on murine Meth A-HM tumors transplanted into BALB/c mice, with complete regression of the tumors being observed in the animals. The possible cachectin activity of mutant 471 was almost the same as that of wild-type TNF. The acute lethal toxicity of mutant 471 in beta-D-galactosamine-sensitized C3H/HeJ mice was 18 times lower than that of wild-type TNF. These results suggest that mutant 471 might be a more promising anti-cancer agent than wild-type TNF. |
| |
Keywords: | |
|
|